HDL Cholesterol Efflux Capacity and Incident Cardiovascular Events

被引:1213
作者
Rohatgi, Anand [1 ]
Khera, Amit [1 ]
Berry, Jarett D. [1 ]
Givens, Edward G. [1 ]
Ayers, Colby R. [1 ]
Wedin, Kyle E. [3 ]
Neeland, Ian J. [1 ]
Yuhanna, Ivan S. [2 ]
Rader, Daniel R. [4 ,5 ]
de Lemos, James A. [1 ]
Shaul, Philip W. [2 ]
机构
[1] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Div Cardiol, Dallas, TX 75390 USA
[2] Univ Texas SW Med Ctr Dallas, Dept Pediat, Ctr Pulm & Vasc Biol, Dallas, TX 75390 USA
[3] Emory Univ, Dept Internal Med, Atlanta, GA 30322 USA
[4] Univ Penn, Perelman Sch Med, Dept Genet, Philadelphia, PA 19104 USA
[5] Univ Penn, Perelman Sch Med, Dept Med, Philadelphia, PA 19104 USA
关键词
DENSITY-LIPOPROTEIN CHOLESTEROL; ATHEROSCLEROSIS; ABILITY;
D O I
10.1056/NEJMoa1409065
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
BACKGROUND It is unclear whether high-density lipoprotein (HDL) cholesterol concentration plays a causal role in atherosclerosis. A more important factor may be HDL cholesterol efflux capacity, the ability of HDL to accept cholesterol from macrophages, which is a key step in reverse cholesterol transport. We investigated the epidemiology of cholesterol efflux capacity and its association with incident atherosclerotic cardiovascular disease outcomes in a large, multiethnic population cohort. METHODS We measured HDL cholesterol level, HDL particle concentration, and cholesterol efflux capacity at baseline in 2924 adults free from cardiovascular disease who were participants in the Dallas Heart Study, a probability-based population sample. The primary end point was atherosclerotic cardiovascular disease, defined as a first nonfatal myocardial infarction, nonfatal stroke, or coronary revascularization or death from cardiovascular causes. The median follow-up period was 9.4 years. RESULTS In contrast to HDL cholesterol level, which was associated with multiple traditional risk factors and metabolic variables, cholesterol efflux capacity had minimal association with these factors. Baseline HDL cholesterol level was not associated with cardiovascular events in an adjusted analysis (hazard ratio, 1.08; 95% confidence interval [CI], 0.59 to 1.99). In a fully adjusted model that included traditional risk factors, HDL cholesterol level, and HDL particle concentration, there was a 67% reduction in cardiovascular risk in the highest quartile of cholesterol efflux capacity versus the lowest quartile (hazard ratio, 0.33; 95% CI, 0.19 to 0.55). Adding cholesterol efflux capacity to traditional risk factors was associated with improvement in discrimination and reclassification indexes. CONCLUSIONS Cholesterol efflux capacity, a new biomarker that characterizes a key step in reverse cholesterol transport, was inversely associated with the incidence of cardiovascular events in a population-based cohort.
引用
收藏
页码:2383 / 2393
页数:11
相关论文
共 30 条
[1]
Cholesterol binding, efflux, and a PDZ-interacting domain of scavenger receptor-BI mediate HDL-initiated signaling [J].
Assanasen, C ;
Mineo, C ;
Seetharam, D ;
Yuhanna, IS ;
Marcel, YL ;
Connelly, MA ;
Williams, DL ;
de la Llera-Moya, M ;
Shaul, PW ;
Silver, DL .
JOURNAL OF CLINICAL INVESTIGATION, 2005, 115 (04) :969-977
[2]
Impaired development of atherosclerosis in hyperlipidemic Ldlr-/- and ApoE -/- mice transplanted with Abcg1-/- bone marrow [J].
Baldan, Angela ;
Pei, Liming ;
Lee, Richard ;
Tarr, Paul ;
Tangirala, Rajendra K. ;
Weinstein, Michael M. ;
Frank, Joy ;
Li, Andrew C. ;
Tontonoz, Peter ;
Edwards, Peter A. .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2006, 26 (10) :2301-2307
[3]
Effects of torcetrapib in patients at high risk for coronary events [J].
Barter, Philip J. ;
Caulfield, Mark ;
Eriksson, Mats ;
Grundy, Scott M. ;
Kastelein, John J. P. ;
Komajda, Michel ;
Lopez-Sendon, Jose ;
Mosca, Lori ;
Tardif, Jean-Claude ;
Waters, David D. ;
Shear, Charles L. ;
Revkin, James H. ;
Buhr, Kevin A. ;
Fisher, Marian R. ;
Tall, Alan R. ;
Brewer, Bryan .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (21) :2109-2122
[4]
Boden WE, 2012, NEW ENGL J MED, V367, P189
[5]
Reconstituted High-Density Lipoprotein Attenuates Platelet Function in Individuals With Type 2 Diabetes Mellitus by Promoting Cholesterol Efflux [J].
Calkin, Anna C. ;
Drew, Brian G. ;
Ono, Akiko ;
Duffy, Stephen J. ;
Gordon, Michelle V. ;
Schoenwaelder, Simone M. ;
Sviridov, Dmitri ;
Cooper, Mark E. ;
Kingwell, Bronwyn A. ;
Jackson, Shaun P. .
CIRCULATION, 2009, 120 (21) :2095-U60
[6]
The Ability to Promote Efflux Via ABCA1 Determines the Capacity of Serum Specimens With Similar High-Density Lipoprotein Cholesterol to Remove Cholesterol From Macrophages [J].
de la Llera-Moya, Margarita ;
Drazul-Schrader, Denise ;
Asztalos, Bela F. ;
Cuchel, Marina ;
Rader, Daniel J. ;
Rothblat, George H. .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2010, 30 (04) :796-U343
[7]
Beyond high-density lipoprotein cholesterol levels - Evaluating high-density lipoprotein function as influenced by novel therapeutic approaches [J].
deGoma, Emil M. ;
deGoma, Rolando L. ;
Rader, Daniel J. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 51 (23) :2199-2211
[8]
Diagnosis and management of the metabolic syndrome - An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement [J].
Grundy, SM ;
Cleeman, JI ;
Daniels, SR ;
Donato, KA ;
Eckel, RH ;
Franklin, BA ;
Gordon, DJ ;
Krauss, RM ;
Savage, PJ ;
Smith, SC ;
Spertus, JA ;
Costa, F .
CIRCULATION, 2005, 112 (17) :2735-2752
[9]
Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO
[10]
2-4